Nikesha Mobley, APRN
Acute Care · Henderson, NVNPI 1902384472
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $354 and has fallen 65.6% since, to $122 in 2025.
Across 20 payments — averaging $47.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intra-sana Laboratories$191
- Merz North America, Inc.$160
- Amgen$125
- Kyowa Kirin, Inc.$122
- Intuitive Surgical$117
- Novo Nordisk$58
- plus $176 from 6 others
What the payments were for
- Food & beverage$950100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intra-sana Laboratories | 3 | $191 |
| Merz North America, Inc. | 1 | $160 |
| Amgen | 1 | $125 |
| Kyowa Kirin, Inc. | 1 | $122 |
| Intuitive Surgical | 1 | $117 |
| Novo Nordisk | 3 | $58 |
| Johnson & Johnson | 3 | $56 |
| Boston Scientific | 3 | $45 |
| KCI USA, Inc. | 1 | $22 |
| Redhill Biopharma Inc. | 1 | $22 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
| AbbVie | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$160
- KRYSTEXXA$125
- Da Vinci Surgical System$117
- Reltone 200 Mg$100
- Reltone 400 Mg$100
How this compares
$950 in reported general payments places this provider in the 70th percentile of 129 acute care providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 29 | $29,710 |
| OzempicSemaglutide | 32 | $29,517 |
| EliquisApixaban | 13 | $14,632 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $3,990 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 54 | $1,772 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 51 | $1,114 |
| Oxycodone Hcl | 33 | $971 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 19 | $883 |
| Gabapentin | 35 | $498 |
| Atorvastatin Calcium | 64 | $373 |
| Losartan Potassium | 36 | $370 |
| Montelukast Sodium | 23 | $311 |
| Amlodipine Besylate | 76 | $306 |
| Levothyroxine Sodium | 23 | $300 |
| Lisinopril | 50 | $286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $58 | $29,51732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 129 acute care providers in Nevada.
Other acute care in Henderson
- Mae NekobaHenderson$8K
- Paula SyHenderson$5K
- Deanne OmarHenderson$1K
- Keith MonsayHenderson$682
- Christina RosatiHenderson$374
- Lindsay BarnesHenderson$323
- Eileen JustoLas Vegas$20K
- Marjeana LampsonCarson City$7K
- Krystal CoffmanLas Vegas$6K
- Frank TalonReno$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.